BioCardia (NASDAQ:BCDA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research report released on Friday morning, Benzinga reports. The firm currently has a $4.00 price objective on the stock. HC Wainwright also issued estimates for BioCardia’s Q2 2024 earnings at ($0.10) EPS, Q3 2024 earnings at ($0.11) EPS, Q4 2024 earnings at ($0.16) EPS and FY2028 earnings at $0.27 EPS.

BioCardia Stock Performance

BCDA opened at $3.17 on Friday. BioCardia has a one year low of $2.62 and a one year high of $23.25. The company has a market cap of $5.77 million, a P/E ratio of -0.45 and a beta of 1.37. The business’s 50-day simple moving average is $3.60 and its 200-day simple moving average is $5.41.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) EPS for the quarter. BioCardia had a negative net margin of 2,208.76% and a negative return on equity of 3,638.68%. The business had revenue of $0.06 million during the quarter. During the same quarter in the prior year, the firm posted ($2.55) EPS. As a group, analysts predict that BioCardia will post -6.3 earnings per share for the current fiscal year.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.